SMTL ID : 8tu5.1

Bruton's tyrosine kinase in complex with covalent inhibitor compound 27

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.10 Å

Oligo State

monomer

Ligands

1 x V7I: 1-[(1S,5S,6S)-6-methyl-6-{[(6M,8R)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxy}-2-azabicyclo[3.2.0]heptan-2-yl]propan-1-one

V7I.1: 13 residues within 4Å: Chain A: L.32, G.33, T.34, A.52, E.99, Y.100, M.101, A.102, G.104, C.105, N.108, R.149, L.152 4 PLIP interactions: 4 interactions with chain A Hydrophobic interactions: A:L.32, A:L.152 Hydrogen bonds: A:M.101, A:N.108

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Himmelbauer, M.K. et al., Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis. J.Med.Chem. (2024)

Release Date

2024-06-26

Peptides

Tyrosine-protein kinase BTK: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Tyrosine-protein kinase BTK

Related Entries With Identical Sequence